Andere Sprachen PharmaEssentia Corporation

Aktien

6446

TW0006446008

6446

Schlusskurs Taiwan S.E. Andere Börsenplätze 00:00:00 05.07.2024			% 5 Tage	% 1. Jan.
567 ^TWD	+2.35%		+1.25%	+63.87%

02.07.	PharmaEssentia Corporation gibt Update zum IND-Antrag für die klinische Phase I-Studie zur sequenziellen Behandlung von P1801 nach P1101 bei Patienten mit fortgeschrittenen soliden Tumoren bekannt	CI
28.06.	PharmaEssentia Corporation kündigt Änderungen im Vergütungsausschuss an	CI

Andere Sprachen

Schalten Sie alle Nachrichten frei: Seien Sie als Erster informiert und reagieren Sie vor den Märkten!

100% kostenlose Registrierung

PharmaEssentia Corporation Announces Update on its IND Application of Phase I Clinical Trial of Sequential Treatment of P1801 Following P1101 in Patients with Advanced Solid Tumors	02.07.
OPINIONI DEGLI ANALISTI DEL GIORNO : Repsol, LVMH, Enel, Hermès, Intensa, Moncler, BASF, NVIDIA, Nike, TIM, Nordex, Shell...	01.07.
PharmaEssentia Corporation Announces Changes to Remuneration Committee	28.06.
Pharmaessentia Corporation Announces Term Expiration of Their Fourth Remuneration Committee	27.05.
Pharmaessentia Corporation Announces Changes to Members of Third Audit Committee	27.05.
Pharmaessentia Corporation Announces Appointments to Board of Directors	27.05.
PharmaEssentia Corporation Provides an Update on Submission of P1101 PhaseIII Clinical Study Protocol for Pre-fibrotic/Early PMFor Overt PMF at Low to Intermediate-1 Risk to China NMPA	21.05.
PharmaEssentia Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	13.05.
Pharmaessentia Corporation Announces Taiwan MOHW Approved the IND Application of Phase I Clinical Trial of P2203 in Principle	03.05.
PharmaEssentia Corp. Submits Phase III Clinical Study Protocol of P1101 for Pre-fibrotic/ Early PMF or OvertPMF at Low to Intermediate-1 Risk to China NMPA	26.04.
PharmaEssentia Corp. Announces Submission of Marketing Authorization Application of BESREMi (Ropeginterferon alfa-2B) for PV in Colombia	24.04.
PharmaEssentia Corporation cancelled the transaction announced on April 2, 2024	16.04.
PharmaEssentia - ANALYSES FIND PATIENTS WITH POLYCYTHEMIA VERA TREATED WITH BESREMI HAD INCREASED PROBABILITY OF ACHIEVING COMPLETE HEMATOLOGIC RESPONSE	02.04.
PharmaEssentia Corporation announced a financing transaction	02.04.
PharmaEssentia Corp. Announces Submission of Marketing Authorization Application of BESREMi (Ropeginterferon Alfa-2b) for PV in Brazil	28.03.
PharmaEssentia Corporation Updates on IND Application of Phase I Clinical Trial of Sequential Treatment of P1801 Following P1101 in Patients with Advanced Solid Tumors to TFDA	04.03.
PharmaEssentia Corporation Submits IND Application of Phase I Clinical Trial of P2203 to Taiwan Food and Drug Administration	04.03.
PharmaEssentia Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	27.02.
PharmaEssentia Corporation(TWSE:6446) added to Taiwan TAIEX Index	19.02.
Soleno Therapeutics Names Meredith Manning as Chief Commercial Officer	24.01.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen PharmaEssentia Corporation

Aktien

6446

TW0006446008

6446

Andere Sprachen

Filter